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ABSTRACT OF THESIS

ASSOCIATION BETWEEN DISPENSING CHANNEL AND
CHRONIC OBSTRUCTIVE PULMONARY DISORDER EXACERBATIONS
AMONG MEDICARE BENEFICIARIES
Elderly patients with chronic obstructive pulmonary disorder may be at increased risk of
exacerbation due to physical and cognitive deficits that make proper inhaled medication
adherence more difficult despite consistent medication access. This retrospective study utilized
administrative medical and pharmacy claims data to examine the likelihood of having a COPD
exacerbation requiring acute medical care by means of an emergency room visit or
hospitalization in elderly patients receiving maintenance COPD medications from mail order and
retail pharmacies. It was hypothesized that mail order patients would be more likely to experience
exacerbations despite differences in medication access when compared to retail patients. The
primary outcome of interest was exacerbation frequency expressed as the incidence density rate,
and the secondary outcome was the proportion of days covered (PDC). The incidence rate ratio
for acute exacerbations was not significantly different for mail order and retail groups, indicating
patients using mail-order pharmacies were not significantly more likely to experience an
exacerbation requiring acute medical care. Despite insignificant differences in incidence rates,
mail order patients had significantly higher adherence rates.
KEYWORDS: Chronic Obstructive Pulmonary Disorder, Acute Exacerbations, Medicare,
Adherence, Dispensing Channel
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Section One: Background
Introduction
Chronic obstructive pulmonary disorder (COPD) is an incurable, progressively life threating
disease that is projected to be the third leading cause of death by 2020. [1] Although the exact
prevalence is often underestimated, studies have suggested that prevalence of COPD increases in a
stepwise manner with age. [1-3] Medication adherence, evidenced by a high proportion of days
covered (PDC), has been associated with fewer respiratory related emergency room visits and
hospitalizations for COPD patients in general. [4] The complex regimens used to manage COPD
patients, however, may be more problematic in older adults as physical and cognitive changes make
proper adherence more difficult despite increased PDC rates. [5]. While several studies have linked
obtaining maintenance medications through mail order to increased adherence rates for diabetes,
hypertension, and hyperlipidemia [6, 7] ,few have explored the relationship between the dispensing
channel and adherence rates or outcomes for individuals with chronic respiratory disorders. [8]
Chronic Obstructive Pulmonary Disorder in Geriatric Populations
Burden of Disease
Chronic Obstructive Pulmonary Disease (COPD) is a life threatening disorder
characterized by progressive airflow limitation from chronic inflammation and structural changes
in parenchymal tissues. [9] Estimates of the true burden of COPD are often underreported;
however, the prevalence is estimated at approximately 14% in patients over 64 years old. [5] As
the population ages, the prevalence is believed to increase in a stepwise manner. The natural course
of COPD is marked by recurrent exacerbations associated with decreased lung function, lower
quality of life, faster disease progression, and increased mortality. [10] These social implications
coupled with the financial burden associated with high healthcare utilization have prompted the
Centers for Disease Control and Prevention (CDC) to list reducing COPD-related emergency room
visits by 30% and COPD-related hospitalizations by 10% by 2020. [11]
Complexities of Medical Management
Adequate medication adherence is a key factor in reducing exacerbation frequency;
however, medication adherence among patients with COPD is currently suboptimal. [12] A primary
factor associated with poor adherence is complex medication regimens requiring physical
coordination for inhaler usage. [13] Some patients are intentionally non-adherent to medications
and deliberately discontinue therapy. On the other hand, unintentional non-adherence is often
related to cognitive impairment, language barriers, or physical disabilities. [14] Elderly patients
with COPD have highlighted difficulties understanding the medication regimen as a major cause
in therapy lapses. Additional concerns with regard to elderly patients managing their COPD include
visual and dexterity issues preventing the appropriate use of inhaled devices. [15] These challenges
may require interventions beyond medication possession to ensure adequate therapy.
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Implications of Inadequate Intervention
Currently, COPD interventions follow a reactive pattern in which patient- physician
interaction is limited to treatment of acute illness such as exacerbations requiring immediate
medical attention. [16] As a multifactorial, progressive disease, rescue care alone is an inadequate
approach to improving disease prognosis. [17] While maintenance medications are integral, failure
to implement patient care models that address factors beyond medication possession is detrimental
to patient outcomes. Appropriate maintenance pharmacotherapy should be coupled with lifestyle
modifications such as smoking cessation and increased physical activity to proactively reduce the
frequency of acute exacerbations and decrease disease progression. Interdisciplinary care teams
which include primary care providers, nurses, and pharmacists are essential in ensuring continuity
of care for optimal outcomes. [18]
Dispensing Channel and Chronic Disorders
Several studies have linked the use of mail order pharmacies to improved health outcomes
across several chronic disease states such as diabetes, hypertension, and hyperlipidemia due to
higher medication adherence rates. [7, 15] These increased adherence rates have been attributable
to the availability of 90 day supply prescriptions when using mail order. In recent years, many
prescription drug plans have allowed patients to fill 90-day supply prescription regardless of the
dispensing channel. [19] A systematic review of recent studies shows mixed results with regards to
whether the use of a mail order pharmacy improves adherence rates with regards to chronic disease.
[7] Even though some patients are financially incentivized to use mail order, the ability to obtain
the same quantity at a local pharmacy may reduce the perceived benefit of mail order use.
Adherence, however, can be measured in various ways, and is difficult to capture through current
acceptable methods.
Medication adherence has been evaluated repeatedly by applying measures such as
medication possession ratio (MPR) and proportion of days covered (PDC) to administrative claims
data. [20] While MPR directly calculates the sum of days’ supply dispensed over a period, PDC
considers the medication supply available throughout the period. [21] Both measures reflect a ratio
that compares a proxy for days of medication compliance in the numerator to an observed period in
the denominator. [22] Unfortunately, these methods are limited because they do not account for
personal attributes that lead to non-adherence. More personalized approaches such as direct
observation and patient surveys are often limited by increased costs. [23] Healthcare providers not
only have the ability to encouraging patients to be more adherent to medications, but also ensure
adherence burdens such as regimen comprehension or administration technique are overcome.
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Section Two: Specific Aims
Specific Aim and Hypothesis
Because the medication regimens for elderly COPD patients are highly susceptible to
adherence problems beyond medication possession, it is critical to assess whether the use of a mail
order or retail pharmacy influences health outcomes of this patient population. This study aimed to
evaluate the frequency of respiratory-related hospitalizations and emergency room visits in patients
filling their COPD maintenance medications at mail order pharmacies compared to patients filling
these medications at retail pharmacies.
The specific aims are as follows:
1. Evaluate the likelihood of having a COPD exacerbation requiring acute medical care by
means of an emergency room visit or hospitalization in elderly patients receiving
maintenance COPD medications from mail order and retail pharmacies
It was hypothesized that Medicare beneficiaries using mail order pharmacies will be more
likely to experience COPD exacerbations requiring hospital care.
2. Measure the adherence rates of elderly patients utilizing mail order and retail pharmacies.
It was hypothesized that there would not be significant difference between adherence rates
among Medicare beneficiaries using different dispensing channels.
The rationale supporting the expressed hypotheses is based upon evidence that medication
possession alone is not indicative of appropriate administration techniques or adequate compliance,
especially with regard to inhaled medications. Furthermore, the hypotheses account for the value
of potential physical interactions with local pharmacy staff in the management of complex
regimens.

Significance
As the population of geriatric COPD patients continues to rise, this study will provide
additional information for developing health system interventions that improve health outcomes in
the presence of adequate medication access. By improving health outcomes and proper medication
adherence, we not only reduce the morbidity and mortality associated with COPD, but also reduce
overall healthcare spending and utilization linked to preventable events.

Approach
A randomized trial to evaluate the effect of dispensing channel on health outcomes would
need to mimic plan benefit designs with mandatory home delivery or retail services. Mandatory
mail order has been shown to negatively influence adherence rates and thusly therapy effectiveness.

3

[24] A design in which the action of randomization can potentially influence the outcome due to
human preference would yield inherently biased results; therefore, an observational study
controlling for known confounders while allowing patient preference would be more desirable.
Previous studies have investigated the association between medication adherence and dispensing
channel across several chronic disease states and medication classes. [7] Few of these studies have
focused on Medicare eligible populations and even fewer have examined the impact on COPD.
Because the results of these studies have generally concluded there is little difference in adherence
rates when using mail order over retail pharmacies, it is important to evaluate any variations in
health outcomes and quality of care for each dispensing channel. Pharmacists are uniquely trained
to assist ambulatory patients in the management of chronic disorders, including COPD. With
frequent physical pharmacist interaction, patients can be assessed for regimen comprehension as
well as administration technique. This is a benefit not available through mail order pharmacies.

Section Three: Methodology

Research Design
Data Source and Overall Approach
This retrospective, observational study focused on retired beneficiaries enrolled between
January 1, 2007 and January 1, 2012 in a Medicare Advantage plan. De-identified and internally
linked paid claims with respect to prescriptions, inpatient services, outpatient services, and personlevel enrollment information was obtained directly from one of the nation’s largest claims
databases, the Humana Comprehensive Health Insights Outcomes Data. Data extraction was
completed through consultation with a trained data analyst. Due to the de-identified nature of the
data, informed consent was not required from study participants.
A new-user design approach with an active comparator was applied in order to capture the
impact of the dispensing channel on the outcomes. While utilizing new-users may limit the
observation of study participants with more advanced disease, this approach reducing the challenge
of confounding by indication. The active comparator was necessary for the purposes of this study
because of the nature of the specified exposure criteria.
Inclusion/Exclusion Criteria
The sample was restricted to patients aged 65 years and older who were diagnosed with
COPD as defined by the following: chronic bronchitis (ICD-9 codes 490-491), emphysema (ICD9 code 492), bronchiectasis (ICD-9 code 494), or chronic airway obstruction (ICD-9 code 496).
Inclusion was limited to patients who were continuously enrolled in a Medicare plan with both
medical and pharmacy benefits for at least eight months between January 1, 2007 and January 1,
2012. A minimum eight month enrollment period was required in order to observe both a six month
preliminary period prior to diagnosis and the subsequent filling of two qualifying inhaled
prescriptions. Federally approved inhaled prescription medication for the chronic management of
COPD include long-acting beta agonists (LABA), inhaled corticosteroids (ICS), inhaled antimuscarinics, or a combination product containing these medication classes throughout the study
period (see Appendix A for a complete list of qualifying inhaled medications).
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Prevalent users, defined as patients with prescription claims for any of the previously
specified inhaled therapies within the 6 months preceding the first coded COPD diagnosis during
the study period, were excluded. Patients who did not obtain a medication refill within 90 days of
expected medication depletion from the initial fill were excluded from the study. Additionally,
patients without available diagnostic data were excluded from the study. A total of 28,657 Medicare
patients were identified as having COPD. Of this cohort, 4,316 patients met the inclusion criteria.
(Figure 3.1) The control population for this study consisted of 3,802 retail pharmacy patients while
the intervention arm consisted of 514 mail order patients. There were 512 patients in each treatment
arm following propensity score matching.
Figure 3.1 Flow Chart of Sample Selection
Medicare beneficiaries aged 65 using
inhaled medications (N=28,657)
Excluded patient with less than 2
prescription fills (N=11,302)
Patients with at least 2 COPD related
prescription fills (N=17,355)
Greater than 90 days gap in therapy
(N= 7,822)
Patients assesed for outcomes data
(N= 9,533)
Missing diagnostic data (N=5,217)
Cohort before matching
(N=4,316)
Mail Order (N=514)

Retail (N=3,802)

1:1 Propensity Matched Cohort
(N=1028)
Unable to identify a macth (N=2)

Retail (N=512)

Mail order (N=512)
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Study Period
The study period consisted of three unique time-frames or points: a pre-index period, index
date, and follow-up. (Figure 3.2) The COPD index date was defined as the first prescription claim
for a maintenance COPD inhaler following an initial study inclusion diagnosis. A 6-month preindex lookback was performed to ensure only new-users proceeded to follow-up as well as gather
prior medical history. Baseline characteristics such as age, race, and geographical region were
assessed as of the COPD index date. The dispensing channel of the first refill or dispensing of the
second prescription for a maintenance medication determined participant classification as a mail
order or retail users and study follow-up began from that point. Follow-up continued from
assignment through the earliest of 15 months, discontinuation of all maintenance COPD
medications, or termination of either medical or prescription benefits. (Figure 2) Because the
primary aim did not focus on comparing efficacy between drug classes, individuals utilizing
multiple inhalers concurrently were evaluated as a single observation. Furthermore, changes
between therapeutic classes of medications within this period did not constitute discontinuation of
therapy.
Figure 3.2 Flow Chart of Study Design
Pre-Index

Index
(First Refill)

6 months

Initial COPD
Prescription

Mail
Order
Retail

Study end:

Follow-up

The earliest of 15
months,
discontinuation of
therapy, or termination
of coverage

No COPD medication use/
est. baseline medical history

Exposures
The primary exposure was the dispensing channel, mail order or retail pharmacy, for which
the patient filled his or her maintenance COPD medications. Pharmacy type was identifiable
through a binary mail order indicator featured in the claims database. Because it is common for
patients to start new medications at their local pharmacies and switch to mail order once tolerated,
dispensing channel use was defined at the second prescription for a COPD maintenance medication.
A sensitivity analysis (Appendix B) to assess the appropriateness of this exposure definition was
performed by classifying dispensing channel based on initial maintenance COPD medication. The
analysis did not show statistically significant differences in classification and supported the
decision to capture dispensing channel at the first refill.
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Outcomes
The primary outcome of interest was COPD-related exacerbations requiring acute medical
care by means of an emergency room (ER) visit, non-routine outpatient visit, or hospitalization.
Medical visits and hospitalizations were deemed COPD-related through medical claims reflecting
COPD exacerbation diagnosis (ICD-9 CM code 491.21, 491.22, 492.0, 494.10) in the primary
diagnostic position. A list of COPD related ICD-9 codes presented in Table 3.1. Exacerbation dates
and medical setting were also obtained for each event. Medical treatments were only considered
events if they occurred after the follow-up began in order to reduce the impact of immortal time
bias. Patients with an exacerbation coded in multiple medical locations were observed as having a
single exacerbation for analysis purposes.
Secondary outcomes included frequency of exacerbation by medical setting and COPD
medication adherence during the study. The measure of adherence chosen was proportion of days
covered (PDC).
Table 3.1 COPD related ICD-9 diagnostic codes
Diagnostic Codes

Description

490.00

Bronchitis, not specified as acute or chronic

491.00

Simple chronic bronchitis

491.10

Mucopurulent chronic bronchitis

491.20

Obstructive chronic bronchitis without exacerbation

491.21

Obstructive chronic bronchitis with (acute) exacerbation

491.22

Obstructive chronic bronchitis with acute bronchitis

492.00

Emphysematous bleb

492.80

Other emphysema

494.00

Bronchiectasis without acute exacerbation

494.10

Bronchiectasis with acute exacerbation

496.00

Chronic airway obstruction, not elsewhere classified

Abbreviations: ICD-9, International Statistical Classification of Diseases and Related Health Problems, Version 9

Statistical Analysis
Baseline Comparisons of Treatment Groups
Summary statistics were used to describe each cohort. Continuous measures were
described using means and standard deviations while categorical variables were described using
percentages. Continuous and categorical variables were also compared between each dispensing
channel using standard t-tests and chi-square test, respectively with standardized differences to
assess similarities of each dispensing arm.
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Estimating the Propensity Score
In efforts to reduce selection bias, a propensity score was estimated using nine variables:
age, gender, geographical region, race, history of diabetes mellitus, history of heart failure, smoking
status, quantity of pre-index prescription claims, pre-index medical expenses [25-27]. A directed
acyclic graph was compiled to determine the minimum sufficient variable set for analyzing the
association between the specified exposure and primary outcome. (Figure 3.3) These variables were
chosen due to their likelihood of influencing the outcomes of interest or a patient’s decision to
choose mail or retail pharmacy to fill maintenance medications. A logistic regression model, which
regressed dispensing channel (mail order vs retail pharmacy) on the aforementioned baseline
characteristics to estimate the propensity score [28-30].
Figure 3.3 Directed Acyclic Graph

Matching on the Propensity Score
Mail order and retail patients were matched 1:1 on the propensity score using a radius
method optimized for the closeness of the propensity scores. [28] There were significantly more
control (retail) patients than were intervention (mail order) patients. The matching process
generated matches with absolute differences between propensity scores no greater than 0.02.
Baseline characteristics were then compared between the matched and unmatched patients using
means and standard deviations for continuous variables and counts and percentages for categorical
variables. In order to check the balance of the propensity score estimation, standardized differences
and p-values were used to quantify the difference between dispensing channels.
Estimating Effect
An intention-to-treat analysis as of the second prescription fill was used. Each study
participant was followed from dispensing arm classification to the study end or medication
discontinuation regardless of whether he or she continued to refill medications at the original
pharmacy type.
All outcomes were analyzed in both the overall and propensity score matched cohorts. The
primary outcome of interest was the frequency of acute COPD exacerbations during the observed
study period, expressed as incidence rates. Incidence rates were estimated with the dependent
variable, count of events, and an offset variable of total time the patients were exposed to an inhaled
maintenance medication filled through one of the dispensing channels. An incidence rate ratio
(IRR) and 95% confidence interval (CI) was then estimated by Poisson regression. As a secondary

8

outcome, incidence rates by each of three exacerbation settings; outpatient, emergency room, and
hospital admittance, were compared in the same manner as the primary outcome of interest.
Additionally, adherence rates, reported as PDC, were calculated for all patients with at least two
consecutive fills following dispensing channel assignment. The PDC algorithm truncated fill dates
occurring outside the observation window and adjusted fill dates to reflect early refills during the
study period. The PDC means were compared using a two-sample t-test and paired t-test for the
unmatched and propensity score matched cohorts, respectively. The percentage of patients meeting
adequate adherence, defined as a PDC greater than or equal to 0.8, were also reported. These
measures were compared using chi-square tests. All analysis were performed using SAS software
version 9.4.
Section Four: Results
Overall Sample Description
The study sample consisted of 4,316 participants, of whom 514 used a mail order pharmacy
and 3,802 used a retail pharmacy. The baseline characteristics of retail and mail order patients are
described in Table 4.1. Prior to propensity score matching, patients using mail order pharmacies
tended to have fewer unique prescription claims and lower medical spend during the pre-index
period (p < 0.001). Retail patients were more likely to reside in the southern region (p<0.001) while
mail order patients were more likely to reside in western and mid-western regions (p =0.003 and
p= 0.02, respectively). All other measured covariates were similar between dispensing channels.
Table 4.1 Baseline Characteristics of Study Sample
Variable

Retail
(N=3802)

Age
Male
White

Mail Order
(N= 514)

Overall Sample
(N= 4,316)

SD of the
Mean/Median
(%)

pvalue

Demographic Characteristics
73.92 ± 7.64
73.28 ± 7.45
73.84 ± 7.62
1823 (47.95)
235 (45.72)
2058 (47.68)
3381 (88.93)
460 (89.49)
3841 (88.99)

-8.43
-4.46
1.83

0.08
0.34
0.70

1047 (27.54)
141 (3.71)
2210 (58.13)
404 (10.63)

10.40
-2.18
-18.71
14.67

0.02
0.65
<0.001
0.003

0.31
-3.87
-5.64

0.95
0.42
0.22

6.85

<0.001

1.35

<0.001

Region
Midwest
Northeast
South
West
Diabetes
Heart Failure
Smoker
Prior Monthly Medical
Expenses ($),
median(IQR)
Prior Monthly
Prescription Claims
median(IQR)

166 (32.30)
17(3.31)
251 (48.83)
80 (15.56)

1213 (28.10)
158 (3.66)
2461 (57.02)
484 (11.21)

Contributing Comorbidities
1026 (26.99)
138 (26.85)
1164 (26.97)
814 (21.41)
102 (19.84)
916 (21.22)
372 (9.78)
42 (8.17)
414 (9.59)
Indicators of Prior Health Status
3,503.52
1,751.88
3,211.30
(10,721)
(4,430)
(9,848)
8.67
(13.6)

5.92
(7.52)

8.16
(12.93)

Note. Continuous variables are presented as means ±standard deviation; dichotomous variables are presented as N (%)
Indicators of Prior Health expressed as medians and IQR
Abbreviation: SD, Standardized Differences; IQR, interquartile range
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Propensity score matching
The 1:1 radius matching technique, which was maximized on closeness of the propensity
score, generated matches for 513 mail order patients to retail patients within an absolute difference
of less than or equal to 0.02 of the propensity score. Only one mail order patient was unable to be
successfully matched to a retail patient with a similar propensity score. The baseline characteristics
of each dispensing arm in the matched cohort are described in Table 4.2. Post-matching, all
standardized differences were less than 10%. The only covariates that differed by more than 5%
were related to geographic region (West and Midwest) and monthly medical expenses during the
pre-index period, exceeded differences of 5 percent.
Table 4.2 Baseline Characteristics of Mail Order and Retail Participants in the Propensity Score
Matched Sample
Variable

Retail
(N=512)

Mail order
(N=512)

SD of the
Mean/median
(%)
Demographic Characteristics

Variance
Ratio

p-value

Age

73.50 ± 7.03

73.28 ± 7.45

-2.98

1.12

0.63

Male

234 (45.70)

235 (45.72)

0.03

1.00

0.99

White

456 (89.06)

460 (89.49)

1.39

1.04

0.82

Region
Midwest
Northeast
South
West

178 (34.77)
24 (4.69)
240 (46.88)
70 (13.67)

166 (32.30)
17 (3.31)
251 (48.83)
80 (15.56)

-5.23
-7.04
3.92
5.35

1.04
1.40
1.00
1.11

0.40
0.26
0.53
0.39

Contributing Comorbidities
Diabetes

130 (25.39)

138 (26.85)

3.32

1.04

0.60

Heart Failure

107 (20.90)

102 (19.84)

-2.61

1.04

0.68

36 (7.03)

42 (8.17)

4.30

1.15

0.50

Smoker

Indicators of Prior Health Status
Prior Monthly
Medical Spend ($)
Prior Monthly
Prescription Claims
median(IQR)

2,091.92
(6,737)

1,751.88
(4,430)

7.09

1.19

0.17

5.60
(7.20)

5.92
(7.52)

1.47

1.04

0.06

Note. Continuous variables are presented as means ±standard deviation; dichotomous variables are presented as N (%)
Indicators of Prior Health expressed as medians and IQR
Abbreviation: SD, Standardized Differences; IQR, interquartile range
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Effect on acute exacerbations
Prior to matching, retail pharmacy patients had a higher incidence rate of an acute
exacerbation when compared to patients using mail order pharmacies (2.41 per 10 person years vs.
2.07 per 10 person years). The difference in rates, however, was not found to be statistically
significant (IRR 0.86; 95% CI, 0.63- 1.17; Table 4.3). Retail patients also had higher incidence
rates for exacerbations treated in an emergency room setting; however, this difference was not
found to be significant. The rates were the same for both outpatient and hospital settings prior to
matching.

Table 4.3 Event rates of acute exacerbation in a cohort of COPD patients using retail and mail
order pharmacies
Before Propensity Score
Matching

Retail (N=3802)

Mail Order (N=514)

Event
, (n)

Personyears

IR/ 10
PY

Event
(n)

Personyear

IR/ 10PY

IRR (95% CI)

Acute Exacerbation

732

3,035.19

2.41

84

404.28

2.07

0.86 (0.63- 1.17)

Outpatient

441

3,035.19

1.45

52

404.28

1.45

0.88 (0.64- 1.23)

Emergency

118

3,035.19

0.39

9

404.28

0.22

0.57 (0.27- 1.20)

Hospitalization

173

3,035.19

0.57

23

404.28

0.57

1.00 (0.61-1.62)

3783

3,035.19

12.46

450

404.28

11.13

0.89 (0.80- 0.99)

Office Visit, Unspecified

Abbreviations: PY, person-years; IR, incidence rate; IRR, Incidence Rate Ratio; CI, confidence interval

Overall, results following matching continued to show slightly lower incidence rates for
mail order patients, regardless of treatment setting. Acute exacerbation incidence rates were 2.44
per 10 person years and 2.07 per 10 person years for retail and mail order patients, respectively.
The difference in these rates, however, remained statistically insignificant (IRR 0.85; 95% CI, 0.591.23; Table 4.4).

Table 4.4 Event rates of acute exacerbation and office visits in a matched cohort of COPD
patients using retail and mail order pharmacies
After Propensity Score
Matching

Acute Exacerbation
Outpatient
Emergency
Hospitalization
Office Visit, Unspecified

Retail (N=512)

Mail Order (N=512)
IRR (95% CI)

Event
, (n)

Personyears

IR/ 10
PY

Event
(n)

Personyear

IR/ 10PY

84
53
10
21

343.62
343.62
343.62
343.62

2.44
1.54
0.29
0.61

84
52
9
23

404.28
404.28
404.28
404.28

2.07
1.45
0.22
0.57

0.85 (0.59-1.23)
0.83 (0.54- 1.27)
0.77 (0.31- 1.91)
0.93 (0.49- 1.75)

430

343.62

12.51

450

404.28

11.13

0.89 (0.78- 1.02)

Abbreviations: PY, person-years; IR, incidence rate; IRR, Incidence Rate Ratio; CI, confidence interval
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Effect on adherence rates
The adherence rates, defined as proportion of days covered (PDC), were significantly lower
for retail patients (0.66 ± 0.24; 95% CI 0.65-0.67) when compared to mail order patients (0.79 ±
0.20; 95% CI, 0.77-0.81) in the overall sample population (p <0.001, Table 5). While the average
PDC in mail order patient was identical in the matched cohort, the average retail PDC was slightly
lower at 0.63. The difference in mean adherence rates continued to be significantly different in the
matched cohort (p< 0.001, Table 6). Neither mail order or retail pharmacy patients had and overall
adherence rate indicative of adequate adherence (pdc ≥ 0.8), but there were nearly twice as many
mail order patients that were adequately adherent (54.81%) when compared to retail patients in the
overall sample and matched cohort (29.77% and 54.81%, respectively).

Table 4.5 Inhaled maintenance medication adherence rates in COPD patients using mail order and
retail pharmacies
Retail

Mail Order

p-value

N=3389
0.66 ± 0.24
1132 (29.77)

N= 416
0.78 ± 0.20
228 (54.81)

<0.001
<0.001

N=410
0.63 ± 0.24
117 (28.54)

N= 416
0.78 ± 0.20
228 (54.81)

<0.001
<0.001

Before Propensity Score Matching
PDC
Adherent† (%)
After Propensity Score Matching
PDC
Adherent† (%)
Abbreviations: PDC, proportion of days covered
†Adherence, PDC greater than or equal to 0.80

Section Five: Discussion and Conclusions
Discussion
This population based study examining the association between dispensing channel and
acute COPD exacerbations among Medicare patients did not yield statistically significant findings;
however, there are notable trends within this population that should be examined with further
studies. Pharmacy benefit managers have promoted mail order use as a means to increase
medication access and therefore improve adherence. Medication adherence may be defined as a
PDC greater than or equal to 0.80. By this definition, neither retail nor mail order elderly COPD
patients achieved adequate adherence. Patients using mail order pharmacies not only yielded higher
PDC rates, but also had a significantly greater percentage of patients achieve adequate adherence
per the definition.
As adherence to medication increases, outcomes should improve as long as the medication
is an efficacious treatment option. Despite superior adherence rates in mail order patients, there
were insignificant differences in incidence rates of exacerbation between the two groups. The
findings suggest that apparent medication access alone is not indicative of appropriate medication
adherence, especially when administration techniques are critical to therapy efficacy. Because
COPD is such a complex chronic condition, there may be an increased need to implement disease
management programs focusing on factors beyond medication access that contribute to decreased
exacerbation frequency and improved outcomes. These results could lead one to believe that a large
portion of medication dispensed to mail order recipients is wasted to either voluntary nonadherence or inappropriate medication administration.
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A major strength of this study was national representation of a large number of Medicare
beneficiaries of varying ages. The sample is not only representative of an understudied population
in which COPD is a highly prevalent disease, but also accounts for demographic traits that are
applicable to disease progression. Furthermore, propensity score matching helped reduce the effects
of confounding variables. There is limited data available that highlights which factors make a
patient more or less likely to fill medications at a retail or mail order pharmacy. The low predictive
value of the propensity score can be explained by the fact that patient preference, a key driver in
pharmacy choice, is not measureable through administrative claims data.
It was hypothesized that mail order patients would be more likely to experience acute
exacerbations. The primary rationale behind the hypothesis took into account the potential for direct
interaction with pharmacy personnel for retail patients. Unfortunately, this was not a measurable
attribute utilizing claims data. As prescription volume increases, retail pharmacists and support
staff have less time to actively counsel and assess appropriate medication use. Taking advantage of
opportunities available through retail pharmacies to encourage medication regimen compliance
could help reduce exacerbations, especially in geriatric populations requiring additional assistance.
Currently, the lack of difference in exacerbation rates coupled with increased adherence rates
among mail order patients contradicts the general notion that medication adherence improves
patient outcomes.
One possible explanation of the failure of this study to identify a significant difference in
exacerbation rates is related to potentially observing patients with less severe disease through a
new-user design. While some patients may only begin treatment after the disease has significantly
progressed, it is possible that the participants in this study were identified the earlier stages of
disease. Balcells et al. demonstrated that one-third of newly diagnosed COPD were identified as a
result of a COPD exacerbation requiring acute care. [31] These same patients also had a decreased
risk of re-hospitalization when compared to patients with an established COPD diagnosis. A
relatively healthy population is supported by the low incidence rate ratio of exacerbations compared
to reported averages ranging from low as 0.09 to 2.4 per patient per year. [32] Additional studies
that identify patients of varying COPD stages may show more difference between the two
dispensing channels. Additionally, neither mail order nor retail patients in this population achieved
adequate adherence overall. While the difference in adherence may be statistically significant, this
difference could potentially not translate to clinical significance if the additional access is not
sufficient to prevent additional exacerbations.
It was also hypothesized that there would be no significant difference in the adherence rates
between mail order and retail patients. The most prominent explanation for this difference is the
financial incentives associated with mail order use.[33] While 90-days supply prescriptions can be
filled at both retail and mail order pharmacies, medication affordability makes filling medications
through mail order more economically feasible. The majority of the inhaled maintenance
medications are still branded medications and could cost significantly more at a retail pharmacy,
thusly reducing the ability of Medicare patients using this dispensing channel to refill their
medications.
There were several limitations to this study. Firstly, there was potential opportunity for
misclassification of dispensing arm due to the intention to treat analysis. It is common for patients
starting a new medication to begin the initial prescription at the local pharmacy, especially when
the timing of therapy initial is critical. While most patients tended to fill their maintenance
medications through a single dispensing channel (mail order or retail pharmacy), there was a
possibility that patients could alternate between the two as frequently as desired throughout the
study period. A dispensing sequence sensitivity analysis showed that there was little difference in
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classification for patients when assigned at the second prescription when compared with the initial
prescription (Appendix B).
Secondly, several outpatient events were nonspecific as acute or chronic in nature as
defined by the ICD-9 code selected from the provider. Issues related to ambiguous coding could be
reduced by including prescription data that also captured antibiotics and/or steroid prescriptions
filled on the same day as the medical treatment date of COPD related event. Outpatient visits with
non-specific codes were deemed as routine visits for the purpose of this study. Although not an
official outcome of this study, post-hoc analysis showed no significant difference in the rates of
office visits (unspecified as acute or an exacerbation) between groups in the matched cohort.
Without additional data, it is unclear whether the specificity of the outcome definition significantly
influenced the study results.
Lastly, current adherence measures through administrative claims are a proxy for actual
adherence and cannot take into account a patient’s true actions. This study was unable to distinguish
patients who requested medication refills from patients taking advantage of automatic refill
programs. It is plausible to consider mail order patients increased adherence rates were attributable
to automatic refill programs rather than actual medication adherence. While automatic refill
programs and patient reminder systems are also prevalent at local pharmacies, a primary difference
in the application of these types of programs is the need for retail patients to visit a brick-andmortar pharmacy to receive medications that may have been automatically refilled. The PDC
algorithm used to estimate adherence reduces the impact of automatic refill programs in either arm
by adjusting fill dates when overlap occurs.

Conclusion
There is no significant difference in exacerbation frequency among Medicare beneficiaries
using mail order pharmacies when compared to retail pharmacies. Increased medication adherence
rates have been repeatedly associated with both mail order pharmacies and fewer exacerbations in
patients with COPD; however, limitations of current adherence measures, unfortunately, make
examining this association difficult. Further studies are needed to examine the impact of direct
patient interaction in a retail environment as compared to self-management with a mail order
pharmacy.
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Appendices
Appendix A
Table A1 Federal Drug Administration Approved Inhaled Maintenance COPD Medication
between 2007-2011
Brand

Generic

Inhaler
Type
Corticosteroids
MDI

Alvesco®

ciclesonide

Asmanex®
Twisthaler
Flovent® Diskus

mometasone furoate

DPI

fluticasone propionate

DPI

Flovent® HFA

fluticasone propionate

MDI

Pulmicort
Flexhaler®

budesonide inhalation

DPI

QVAR

beclomethasone
dipropionate

MDI

Usual Adult Dosage

Product NDC
(USA)

80-320 mcg inhaled
BID

63402-0711
63402-0712
54868-5989
54868-5990
00085-1341
00085-1461
00173-0600
00173-0601
00173-0602
00173-0718
00173-0719
00186-0916
00186-0917
21695-0291
54868-5844
59310-0202
59310-0204
16590-0860
50090-1342
54868-5857
54868-5858

220-440 mcg inhaled
QD or BID
100-500 mcg inhaled
BID
88-440 mcg inhaled
BID
360-720 mcg inhaled
BID

40-320 mcg inhaled
BID

Serevent® Diskus

Long Acting Beta Agonists (LABA)
salmeterol xinofate
DPI
50 mcg inhaled BID

Foradil ® Aerolizer

formoterol fumurate

Advair® Diskus

Corticosteroid/ LABA combination
fluticasone propionate/
DPI
1 inhalation BID
salmeterol

DPI

12 mcg inhaled BID

00173-0520
00173-0521
00085-1401
00085-1402

Advair® HFA

fluticasone propionate/
salmeterol

MDI

2 inhalations BID

Dulera®

mometasone furoate/
formoterol fumarate
dihydrate
Budesonide/ formoterol
fumarate Dihydrate

MDI

2 inhalations
BID

00173-0695
00173-0696
00173-0697
00173-0715
00173-0716
00173-0717
08546-1001
08572-0601

MDI

2 inhalations
BID

18603-7020
18603-7220

18 mcg inhaled QD

59700-7541

Symbicort®

Muscarinics
Spiriva Handihaler®

tiotropium bromide

DPI

Abbreviations: NDC, national drug code; HFA, hydrofluoroalkane; DPI, dry powder inhaler; MDI, metered-dose inhaler; QD,
once daily; BID, twice daily
References[34]
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Appendix B
Because the exposure, dispensing channel, was highly dependent upon patient preference, it was
important to identify the best method of classifying the exposure arm. An intention-to-treat
analysis as of the second prescription was utilized in the study. The robustness of this
classification strategy was assessed with a sensitivity analysis. Table B1 compares the dispensing
sequence of all patients with qualifying COPD prescriptions when analysis was performed from
either the initial prescription or the second prescription. The intention-to-treat analysis yielded
accurate classification for approximately 90 percent of all participants through the study
observation period regardless of whether the dispensing channel was established at the initial
prescription or the second prescription. Figure B1 demonstrates the percentage of patients who
remained in the determined dispensing channel throughout the study in both the overall and
matched cohorts.

Table B1 Fill Sequence Comparison in All COPD Patients
Initial Prescription (n=28,075)
Fill Sequence of Dispensing Channel
Switch

Second Prescription
(n= 17,355)

N

%

N

%

25,314

90.17

15,494

89.28

At 2nd Observation

1155

4.11

738

4.25

After 2nd Observation

1606

5.72

1123

6.47

No Switch

Figure B1: Intention-to-treat Classification Accuracy in Study Population

Percent Agreement (%)

94
92
90
88

Initial Rx

86

Second Rx

84
82
80

Overall

PS Matched

Abbreviations: Rx, prescription; PS, propensity score

There are two reasons why it was desirable to classify patients as of the second prescription fill.
The first reason is that it is common for patients beginning a new prescription to begin at the local
pharmacy and transition to a mail order pharmacy once they are stabilized on the medication.
Secondly, classifying exposure as of the second fill reduces the impact of immortal time bias on
treatment outcomes. The primary outcome of interest, exacerbations, is closely related to
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medication adherence. There is a portion of time between the first and second fill where we can
neither attribute an exacerbation to the exposure of filling a medication at a particular dispensing
channel nor estimate medication adherence. Had analysis began at the initial prescription, the
exacerbation rate may have been overestimated. The sensitivity analysis demonstrates there was
minimal difference between classifying patients as of the second prescription and the initial
prescription.
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